How do healthtech startups sell to the NHS?

The most important thing to understand is that the NHS as a monolith doesn't exist. It comprises separate trusts and organisations, each with their own procurement processes [#279]. This fragmentation means startups cannot build a viable venture by selling to NHS trusts alone — you'd need to capture an implausible proportion of the market to achieve VC-scale returns [#276].

The practical path is to reverse the logic many founders adopt. Rather than treating the NHS as the primary customer, build revenue and clinical evidence elsewhere first [Ep 28]. Expand internationally, prove the product works, then approach the NHS from a position of credibility. This also requires moving beyond passion and ambition; the NHS evaluates based on outcomes and integration potential, not novelty. Founders often underestimate both the timeline and the need to embed their solution within existing NHS workflows to make reimbursement viable [#324]. Only after you've demonstrated commercial traction and clinical value does an NHS sale become realistic.